vs
Side-by-side financial comparison of PennyMac Mortgage Investment Trust (PMT) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $93.6M, roughly 1.1× PennyMac Mortgage Investment Trust). PennyMac Mortgage Investment Trust runs the higher net margin — 56.0% vs -29.4%, a 85.4% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs -13.3%).
PennyMac Mortgage Investment Trust is a U.S.-headquartered real estate investment trust specializing in residential mortgage assets. It invests in performing and non-performing mortgage loans, mortgage-backed securities, and credit risk transfer instruments, operating across investment management and mortgage servicing segments in the U.S. housing market.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
PMT vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $93.6M | $103.7M |
| Net Profit | $52.4M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 38.6% | -31.7% |
| Net Margin | 56.0% | -29.4% |
| Revenue YoY | -13.3% | 16.9% |
| Net Profit YoY | 12.5% | 3.4% |
| EPS (diluted) | $0.49 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $93.6M | $103.7M | ||
| Q3 25 | $99.2M | — | ||
| Q2 25 | $70.2M | — | ||
| Q1 25 | $44.5M | — | ||
| Q4 24 | $107.9M | — | ||
| Q3 24 | $80.9M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $74.2M | — |
| Q4 25 | $52.4M | $-30.5M | ||
| Q3 25 | $58.3M | — | ||
| Q2 25 | $7.5M | — | ||
| Q1 25 | $9.7M | — | ||
| Q4 24 | $46.5M | — | ||
| Q3 24 | $41.4M | — | ||
| Q2 24 | $25.4M | — | ||
| Q1 24 | $47.6M | — |
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 38.6% | -31.7% | ||
| Q3 25 | 47.4% | — | ||
| Q2 25 | 24.2% | — | ||
| Q1 25 | -14.2% | — | ||
| Q4 24 | 51.1% | — | ||
| Q3 24 | 32.8% | — | ||
| Q2 24 | 40.2% | — | ||
| Q1 24 | 43.6% | — |
| Q4 25 | 56.0% | -29.4% | ||
| Q3 25 | 58.7% | — | ||
| Q2 25 | 10.7% | — | ||
| Q1 25 | 21.8% | — | ||
| Q4 24 | 43.1% | — | ||
| Q3 24 | 51.2% | — | ||
| Q2 24 | 35.7% | — | ||
| Q1 24 | 64.2% | — |
| Q4 25 | $0.49 | $-0.50 | ||
| Q3 25 | $0.55 | — | ||
| Q2 25 | $-0.04 | — | ||
| Q1 25 | $-0.01 | — | ||
| Q4 24 | $0.45 | — | ||
| Q3 24 | $0.36 | — | ||
| Q2 24 | $0.17 | — | ||
| Q1 24 | $0.39 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $190.5M | $197.9M |
| Total DebtLower is stronger | $1.1B | — |
| Stockholders' EquityBook value | $1.9B | $456.1M |
| Total Assets | $21.3B | $638.1M |
| Debt / EquityLower = less leverage | 0.58× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $190.5M | $197.9M | ||
| Q3 25 | $181.0M | — | ||
| Q2 25 | $108.6M | — | ||
| Q1 25 | $204.2M | — | ||
| Q4 24 | $103.2M | — | ||
| Q3 24 | $102.8M | — | ||
| Q2 24 | $336.3M | — | ||
| Q1 24 | $343.3M | — |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $299.0M | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $968.4M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $5.4B | — | ||
| Q1 24 | $5.1B | — |
| Q4 25 | $1.9B | $456.1M | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $1.9B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $1.9B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | $21.3B | $638.1M | ||
| Q3 25 | $18.5B | — | ||
| Q2 25 | $16.8B | — | ||
| Q1 25 | $14.9B | — | ||
| Q4 24 | $14.4B | — | ||
| Q3 24 | $13.1B | — | ||
| Q2 24 | $12.1B | — | ||
| Q1 24 | $12.3B | — |
| Q4 25 | 0.58× | — | ||
| Q3 25 | 0.16× | — | ||
| Q2 25 | 0.65× | — | ||
| Q1 25 | 0.51× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 2.70× | — | ||
| Q2 24 | 2.76× | — | ||
| Q1 24 | 2.60× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2B | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | — | 9.6% |
| Cash ConversionOCF / Net Profit | -137.76× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2B | $-24.8M | ||
| Q3 25 | $-1.3B | — | ||
| Q2 25 | $-2.0B | — | ||
| Q1 25 | $-594.3M | — | ||
| Q4 24 | $-2.7B | — | ||
| Q3 24 | $-983.8M | — | ||
| Q2 24 | $243.8M | — | ||
| Q1 24 | $-342.4M | — |
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -137.76× | — | ||
| Q3 25 | -22.26× | — | ||
| Q2 25 | -267.53× | — | ||
| Q1 25 | -61.39× | — | ||
| Q4 24 | -58.08× | — | ||
| Q3 24 | -23.76× | — | ||
| Q2 24 | 9.59× | — | ||
| Q1 24 | -7.19× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PMT
| Other | $55.0M | 59% |
| Interest Rate Sensitive Strategies | $31.4M | 34% |
| Correspondent Production | $7.2M | 8% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
